

CASE REPORT

Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients

GA Moviglia^{1,2}, G Varela^{1,2}, JA Brizuela^{1,2}, MT Moviglia Brandolino^{1,2}, P Farina¹, G Etchegaray^{1,2}, S Piccone^{1,2}, J Hirsch¹, G Martínez^{1,2}, S Marino^{1,2}, S Deffain^{1,2}, N Coria^{1,2}, A González^{1,2}, M Sztanko^{1,2}, P Salas-Zamora^{1,2}, I Previglio^{1,2}, V Aingel^{1,2}, J Farias¹, CA Gaeta^{1,2}, J Saslavsky¹ and N Blasseti^{1,2}

¹Fundación Regina Mater, Buenos Aires, Argentina and ²Centro de Investigación en Ingeniería de Tejidos y Terapia Celular (CIITT), Universidad Maimónides, Buenos Aires, Argentina

Objectives: With the intention to ameliorate the clinical condition of patients with chronic spinal cord injury (SCI), a program that combines three cell therapies and an appropriate neurorehabilitation program were used to recreate and enhance the natural conditions of SCI repair.

Methods: Vascularization recovery is approached by selective artery infusion of BMMNCs (bone marrow mononuclear cells) to the disrupted area. Eighteen days later, with the aim to restore the specific inflammatory activity, an i.v. infusion of spinal cord specific ETCs (effector T cells) is carried out. With the intention of supplying cellular components for the process of repair, an infusion of autologous neural stem cells (NSCs) through selective feeding artery infusion is carried out, followed by an appropriate neurorehabilitation program.

Results: A total of eight ASIA (American Spinal Injury Association) A patients (five with jeopardized brachial plexus and three without) received the treatment. No severe adverse events was observed in any of the receptor patients: five patients evolved from ASIA A to ASIA D and regained the ability to stand up and, with varying effectiveness, to walk; two patients remained in the same condition, but exhibited motor and sensitive improvements; and one patient could not be evaluated.

Conclusions: These reports suggest that the biological characteristics of acute SCI may be recreated in a comprehensive, safe and effective manner.

Spinal Cord (2009) 47, 499–503; doi:10.1038/sc.2008.164; published online 17 February 2009

Keywords: chronic spinal cord injury; neural stem cell; protective autoimmunity; neurorehabilitation; cellular therapy; scale evaluation

Introduction

The state-of-the-art treatment for chronic spinal cord injury (SCI) may achieve minor neurological function recovery in only <5% of the patients.¹

This report describes the clinical results of three combined cell therapies associated with an appropriate neurorehabilitation program, which intends to recreate and enhance the natural conditions of SCI repair as described earlier.^{2–5} The vascularization recovery is approached by selective artery infusion of BMMNCs (bone marrow mononuclear cells) to the disrupted area.² Eighteen days later, with the aim to restore the specific inflammatory activity,^{3,4} a second cellular therapy is carried out by an i.v. infusion of spinal cord specific ETCs (effector T cells). It is carried out with the intention of opening the blood-brain barrier and for generating a neutropin

microenvironment suitable for NSC repair.^{3–5} The third cell therapy, infusion of autologous NSC through selective feeding artery infusion, is carried out with the intention of supplying the cellular components for the repairing process.^{2,3} Finally, an *ad hoc* neurorehabilitation program was designed with the intention to procure an appropriate NSC spatial distribution to restore neural centers and brainstems. This sequence of cellular therapies, BMMNC-ETC-NSC, was named BEN.²

Adverse events were evaluated by the 'Common terminology criteria for Adverse Events (AE), 2004' developed by the NIH. See definitions on the web at <http://ctep.cancer.gov/reporting/ctc.html>.

Results

Treatment safety

After bone marrow puncture, 3/8 patients presented degree 2 anemia and 1/8 patients presented degree 1 headache and sickness.

Correspondence: Professor GA Moviglia, Fundación Regina Mater, Center for Research, Engineering and Cellular Therapy (CIITT), Maimónides University, Paraguay 2452, Buenos Aires 1121 ABL, Argentina.

E-mail: gmoviglia@gmail.com

Received 19 August 2008; revised 20 September 2008; accepted 9 November 2008; published online 17 February 2009

Table 1 Quantitative assessment scale of treated patients

<i>Motor activity</i>	<i>Definition</i>	<i>Intervening muscles</i>	<i>Joint movement</i>	<i>Spinal cord level</i>
Cephalic support	Active voluntary contraction of neck muscles	Sternohyoid, omohyoid, geniohyoid, digastric, scaleni, rectus capitis	Flexion, extension, rotation and tilt	C1–C5
Static trunk stability	Active and sustained contraction of paravertebral and abdominal muscles that allow trunk stability, at a 90° position with external assistance	Trapezius, romboideus, deltoid, latissimus dorsi, iliocostalis, longissimus, quadratus lumborum, rectus abdominis, internal and external obliques, serratus muscle		
Dynamic trunk stability	Active and sustained contraction of paravertebral and abdominal muscles that allow trunk stability during lateral and antero-posterior movement, without external assistance		Flexion, extension, rotation and lateral tilt	C5–L1
Upper limb mobility	Active voluntary contraction	Shoulder	Deltoid, major and minor pectoral, latissimus dorsi, supraspinatus, infraspinous, teres major, teres minor, subscapularis	C5–C8
		Elbow	Biceps, anterior brachial, brachioradialis, triceps, supinator, pronator	C4–C7
		Wrist	Major and minor palmaris, anterior and posterior lunar, extensor carpi radialis longus	C6–C7
		Hand	Interosae, lumbricals, extensor digitorum, thenar eminence muscles	C8–D1
Pelvis mobility	Active contraction of agonist and antagonist muscles that allows a neutral position of orthostatism without the use of external support	Quadratus lumborum, rectus abdominis, internal and external obliques, transversus abdominis, longissimus, gluteus maximus and minimus, pelvic floor muscles		T7–L4
Pelvic floor contraction	Voluntary contraction of perineo muscles	Coccygeus, superficial transversus perinei muscle, levator ani, anal sphincter		S2–S4
Lower limb mobility	Voluntary active contraction	Hip	Psoas iliacus, gluteus maximus, medius and minimus, adductor magnus, longus and brevis, internus and externus obturator	L2–S1
		Knee	Quadriceps, crureus biceps, semimembranosus, semitendinosus, tensor muscle	L3–S2
		Ankle	Gastrocnemius, soleus, lateral penoneal, tibialis posterior and anterior, interosae	L5–S2
		Foot	Finger flexors and extensor digitorum longus, interosae	L4–S1

Table 2 (a) Initial evaluation and (b) current evaluation

Pat.	Cephalic support	Static trunk stability	Dynamic trunk stability	Upper limb mobility		Pelvis stability	Pelvis floor contraction	Lower limb mobility		Total
				Left	Right			Left	Right	
(a) 1	2	0	0	Shoulder Elbow Wrist Hand	0 0 0 0	0 0 0 0	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	2/105
2	4	0	0	Shoulder Elbow Wrist Hand	2 0 0 0	3 2 0 0	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	11/105
3	6	0	0	Shoulder Elbow Wrist Hand	2 0 0 0	3 2 0 0	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	13/105
4	6	3	0	Shoulder Elbow Wrist Hand	5 5 5 5	5 5 5 5	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	49/105
5	6	2	0	Shoulder Elbow Wrist Hand	4 4 3 2	4 4 3 2	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	34/105
6	6	4	3	Shoulder Elbow Wrist Hand	5 5 5 5	5 5 5 5	1 0 0 0	Hip Knee Ankle Foot	0 0 0 0	53/105
(b) 1 8 m of treat.	4	2	0	Shoulder Elbow Wrist Hand	3 3 0 0	4 3 0 0	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	23/105
2 12 m of treat.	5	3	2	Shoulder Elbow Wrist Hand	4 4 2 1	4 4 3 1	0 0 0 0	Hip Knee Ankle Foot	0 0 0 0	37/105
3 24 m of treat.	5	5	3	Shoulder Elbow Wrist Hand	4 4 4 3	4 4 4 3	2 0 0 0	Hip Knee Ankle Foot	2 0 0 0	54/105
4 6 m of treat.	5	5	5	Shoulder Elbow Wrist Hand	5 5 5 5	5 5 5 5	4 0 0 0	Hip Knee Ankle Foot	3 1 0 0	82/105
5 5 m of treat.	5	3	2	Shoulder Elbow Wrist Hand	5 5 5 3	5 5 5 3	2 0 0 0	Hip Knee Ankle Foot	0 0 0 0	53/105
6 6 m of treat.	5	5	4	Shoulder Elbow Wrist Hand	5 5 5 5	5 5 5 5	4 Not evaluated	Hip Knee Ankle Foot	4 1 0 0	68/105

Abbreviations: Pat., patient; treat., treatment.

During the apheresis procedure, 1/8 patients presented degree 1 arterial hypertension.

After the apheresis procedure, 1/8 patients presented a transitory degree 1 increase of transaminases and hypertriglyceridemia.

No autoimmune reaction, after the infusion of pertinent effector lymphocytes, was observed. It was measured systemically in peripheral blood according to the lymphocyte proliferation index carried out on the day of the i.v. infusion, 48 h, 1 week and 1 month later.

Treatment efficiency

Patients with low cervical injury (patient 5) and thoracic injury (patients 4 and 6) followed a sensory and motor recovery pattern that descended along the trunk and limbs, from proximal to distal endings. This evolution was easily assessable by the ASIA (American Spinal Injury Association) scale and its functional degrees (A-E).

Sensory recovery had three different stages: lack of skin sensibility, followed by dysesthesia episodes that, in many cases, evolved to pain until they finally disappeared and led




Figure 1 (a) MRI of patient 2 in March 2005. (b) MRI of patient 2 in June 2007. MRI, magnetic resonance imaging.



Figure 2 Pictures (a and b) illustrate that in March 2005, patient 2 could only move muscles that belonged to spinal cord roots C3–C4. To sit down or to move, any rehabilitation machine was needed. Pictures (c and d) illustrate that in May 2008, patient 2 could move muscles that belong to spinal cord roots S4–S5. She could sit down without any support and stand up with minimal support.

to a progressive increase from proprioception to tactile discrimination.

Patients with chronic SCI suffered flaccid paralysis at both the injury level and below. Five of the eight patients experienced variable degrees of spasticity of the muscles below the lesion.

After BEN treatment, the functionality of spastic muscles was the first to recover. However, muscles with flaccid paralysis presented an increase in their tone at the first stage, followed by a second stage with predominant spasmotic contractions (producing occasional pain) and, finally, a gradual recovery of strength and muscle functionality. This process was cyclic and lasted for the whole follow-up period of patients treated and rehabilitated suitably (7/8), even in those who received the last BEN treatment 30 months earlier. When this rehabilitation program was interrupted or an unsuitable strategy was applied, the recovery process stopped, although the benefits achieved were not lost.

Patients with high cervical injury (patients 1–3, 7 and 8) achieved a similar sensory and motor recovery; however, the recovered metameric levels followed an atypical progression.

Although motor functions and sensibility of the spinal cord segments below the injury level followed patterns similar to that described earlier, the same functions of the injured metameric segments followed their own pattern that of slower recovery from proximal to distal areas.

In other words, although the patient was able to recover from head and trunk injury in a rapid progressive pattern, the upper limb motility and sensitivity showed slower rate of recovery. Such phenomena are taken as the difference between simply recovering cortico-spinal connections and the need to reconstruct the motor nucleus and sensory ganglia of the injured area, either by regeneration or by neuronal plasticity.

Objective quantification results of the Spinal Cord Functional recovery, carried out according to the scale transcribed in Table 1, are summarized in Table 2a and b.

Figure 1 summarizes the most significant cervical magnetic resonance imaging of patient 2. Figure 2 shows

photographs of patient 2 taken at the beginning of treatment and 34 months after.

Discussion

This report suggests that a combined cellular therapy approach associated to a specific neurorehabilitation scheme may be feasible, safe and effective to promote neural restoration of chronic SCI patients. Further works are under process to certify these findings.

Acknowledgements

The authors acknowledge the highly qualified professional assistance of Perez E, Galindes E, Professor Delgado V, Professor Fernandez Viña R, Vrsalovic F and Professor Shuster GS; the emotional support of Ms Maricel Brandolini, Ms María Luz Moviglia B and Professor Ernesto Goberman; the technical assistance of Ms Carolina Beascochea; and the economic support of Regina Mater and the Scientific Foundation Felipe Fiorelino.

References

- 1 El Masry WS, Tsubo M, Katoh S, El Miligui YH, Khan A. Validation of the American Spinal Injury Association (ASIA) motor score and the National Acute Spinal Cord Injury Study (NASCIS) motor score. *Spine* 1996; **21**: 614–619.
- 2 Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet* 2002; **360**: 427–435.
- 3 Moviglia GA, Varela G, Gaeta CA, Brizuela JA, Bastos F, Saslavsky J. Autoreactive T cells induce in vitro bone marrow mesenchymal stem cells transdifferentiation to neural stem cells. *Cytotherapy* 2005; **8**: 196–201.
- 4 Moviglia GA, Fernández Viña R, Brizuela JA, Saslavsky J, Vrsalovic F, Varela G et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. *Cytotherapy* 2005; **8**: 202–209.
- 5 Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. *Proc Natl Acad Sci USA* 2006; **103**: 13174–13179.